Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non–Small Cell Lung Cancer
Elizabeth S. Waxman, RN, MSN, AOCN®, and Frank V. Fossella, MD
MD Anderson Cancer Center, Houston, Texas
Authors’ disclosures of potential conflicts of interest are found at the end of this article.
Elizabeth S. Waxman, RN, MSN, AOCN®, Thoracic/Head & Neck Medical Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 432, Houston, TX 77030; E-mail: firstname.lastname@example.org
J Adv Pract Oncol 2016;7:514–524 |
doi: 10.6004/jadpro.2016.7.5.4 |
© 2016 Harborside Press®
For decades, the prognosis for patients with advanced-stage non–small cell lung cancer (NSCLC) was bleak, with chemotherapy offering limited benefit and much toxicity. Now, with mutational testing, new generations of targeted therapies, and emerging immunotherapies, the treatment horizon for these patients has greatly expanded. In this article, the authors review molecular targets, biomarkers, as well as immune checkpoint inhibitors, which are having a major impact on the management of this patient population.
For access to the full length article, please sign in